SWAB/NVALT (dutch working party on antibiotic policy and dutch association of chest physicians) guidelines on the management of community-acquired pneumonia in adults

Netherlands Journal of Medicine

Volumn 70, Issue 2, 2012, Pages 90-101

  Wiersinga, W J ^a   Bonten, M J ^b   Boersma, W G ^c   Jonkers, R E ^d   Aleva, R M ^e   Kullberg, B J ^f   Schouten, J A ^g   Degener, J E ^h   Janknegt, R ⁱ   Verheij, T J ^b   Sachs, A P E ^b   Prins, J M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Medical Centre Alkmaar   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e MÁXIMA MEDICAL CENTER   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ Zuyderland Medical Centre   (Netherlands)

Author keywords

Antimicrobial therapy; Community acquired pneumonia; Guidelines

Indexed keywords

AMOXICILLIN; BETA LACTAMASE INHIBITOR; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLAVULANIC ACID; CLINDAMYCIN; COTRIMOXAZOLE; DEXAMETHASONE; DOXYCYCLINE; ERYTHROMYCIN; FLUCLOXACILLIN; IMMUNOGLOBULIN M; LEVOFLOXACIN; LINEZOLID; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; OSELTAMIVIR; PENICILLIN G; PHENETICILLIN; PROCALCITONIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHLAMYDOPHILA; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; COXIELLA BURNETII; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EFFUSION; ENTEROBACTERIACEAE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED PRACTICE; HAEMOPHILUS INFLUENZAE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HOSPITAL ORGANIZATION; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; IMMUNOFLUORESCENCE; IMMUNOMODULATION; IMMUNOTHERAPY; LEGIONELLA; LENGTH OF STAY; LOADING DRUG DOSE; MEDICAL RECORD REVIEW; MONOTHERAPY; MORTALITY; MYCOPLASMA PNEUMONIAE; NETHERLANDS; NOSE SMEAR; OUTPATIENT CARE; PATHOGENESIS; PENICILLIN ALLERGY; PNEUMONIA SEVERITY INDEX; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PROTEIN EXPRESSION; Q FEVER; RISK FACTOR; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SYMPTOM; THORAX RADIOGRAPHY; TREATMENT DURATION;

ADULT; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DISEASE MANAGEMENT; DRUG ADMINISTRATION ROUTES; DRUG RESISTANCE, BACTERIAL; HUMANS; NETHERLANDS; PNEUMONIA; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84858595099     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Bjerre LM, Verheij TJM, Kochen MM. Antibiotics for community acquired pneumonia in adilt outpatients. Cochrane Database Syst Rev. 2009;(4):1-43.
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines o n the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-S72.
3. Schouten JA, Prins JM, Bonten MJ, et al. Revised SWAB guidelines for antimicrobial therapy of community-acquired pneumonia. Neth J Med. 2005;63(8):323-35.
4. NVALT (National Society for Respiratory Physicians). Guideline for Diagnosis and Treatment of Community-acquired Pneumonia (CAP). Alphen aan den Rijn: Van Zuiden Communications; 2003.
5. Verheij T, Hopstaken RM, Prins JM, et al. NHG-standaard Acuut hoesten. Eerste herziening. H&W 2011;54:68-92.
6. Everdingen JJE, Burgers JS, Assendelft WJJ, Swinkels JA, Barneveld TA van ea. Evidence-based richtlijnontwikkeling. Een leidraad voor de praktijk. Houten: Bohn Stafleu van Loghum; 2004.
7. van Kasteren ME, Wijnands WJ, Stobberingh EE, Janknegt R, van der Meer JW. [Optimization of the antibiotics policy in the Netherlands. II. SWAB guidelines for the antimicrobial therapy of pneumonia in patients at home. The Netherlands Antibiotic Policy Foundation]. Ned Tijdschr Geneeskd. 1998;142(17):952-6.
8. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163(7):1730-54.
9. Mandell LA, Bartlett JG, Dowell SF, File TM, Jr., Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37(11):1405-33.
10. Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000;31(2):347-82.
11. ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory Society. Eur Respir J. 1998;11(4):986-91.
12. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax. 2001;56 Suppl 4:IV1-64.:IV1-IV64.
13. SWAB. NethMap 2010 - Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands. Amsterdam: 2010
14. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64 Suppl 3:iii1-iii55.
15. Vegelin AL, Bissumbhar P, Joore JC, Lammers JW, Hoepelman IM. Guidelines for severe community-acquired pneumonia in the western world. Neth J Med. 1999;55(3):110-7.
16. Bohte R, van Furth R, van den Broek PJ. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax. 1995;50(5):543-7.
17. Oosterheert. Diagnosis and treatment of community-acquired lower respiratory tract infections. 2005.
18. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181(9):975-82.
19. van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005;60(8):672-8.
20. Braun JJ, de Graaff CS, de Goey J, Zwinderman AH, Petit PL. [Communityacquired pneumonia: pathogens and course in patients admitted to a general hospital]. Ned Tijdschr Geneeskd. 2004;148(17):836-40.
21. Boersma WG, Daniels JM, Lowenberg A, Boeve WJ, van de Jagt EJ. Reliability of radiographic findings and the relation to etiologic agents in community-acquired pneumonia. Respir Med. 2006;100(5):926-32.
22. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med. 1999;160(2):397-405.
23. Logroscino CD, Penza O, Locicero S, et al. Community-acquired pneumonia in adults: a multicentric observational AIPO study. Monaldi Arch Chest Dis. 1999;54(1):11-7.
24. Ostergaard L, Andersen PL. Etiology of community-acquired pneumonia. Evaluation by transtracheal aspiration, blood culture, or serology. Chest. 1993;104(5):1400-7.
25. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med. 2002;162(16):1849-58.
26. Leroy O, Vandenbussche C, Coffinier C, et al. Community-acquired aspiration pneumonia in intensive care units. Epidemiological and prognosis data. Am J Respir Crit Care Med. 1997;156(6):1922-9.
27. Den Boer JW, Nijhof J, Friesema I. Risk factors for sporadic community-acquired Legionnaires' disease. A 3-year national case-control study. Public Health. 2006;120(6):566-71.
28. Delsing CE, Kullberg BJ, Bleeker-Rovers CP. Q Fever in the Netherlands from 2007 to 2010. Neth J Med. 2010;68(12):382-7.
29. Schimmer B, Morroy G, Dijkstra F, et al. Large ongoing Q fever outbreak in the south of The Netherlands, 2008. Euro Surveill. 2008;13(31).
30. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-50.
31. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377-82.
32. Bont J, Hak E, Hoes AW, Macfarlane JT, Verheij TJ. Predicting death in elderly patients with community-acquired pneumonia: a prospective validation study reevaluating the CRB-65 severity assessment tool. Arch Intern Med. 2008;168(13):1465-8.
33. Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax. 2010;65(10):878-83.
34. Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med. 2005;118(4):384-92.
35. Buising KL, Thursky KA, Black JF, et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax. 2006;61(5):419-24.
36. Kauppinen MT, Lahde S, Syrjala H. Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae. A comparison with streptococcus pneumonia. Arch Intern Med. 1996;156(16):1851-6.
37. Macfarlane JT, Miller AC, Roderick Smith WH, Morris AH, Rose DH. Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis. Thorax. 1984;39(1):28-33.
38. Lahde S, Jartti A, Broas M, Koivisto M, Syrjala H. HRCT findings in the lungs of primary care patients with lower respiratory tract infection. Acta Radiol. 2002;43(2):159-63.
39. Hayden GE, Wrenn KW. Chest radiograph vs. computed tomography scan in the evaluation for pneumonia. J Emerg Med. 2009;36(3):266-70.
40. Syrjala H, Broas M, Suramo I, Ojala A, Lahde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis. 1998;27(2):358-63.
41. Hagaman JT, Rouan GW, Shipley RT, Panos RJ. Admission chest radiograph lacks sensitivity in the diagnosis of community-acquired pneumonia. Am J Med Sci. 2009;337(4):236-40.
42. Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2004;39(2):165-9.
43. Lettinga KD, Verbon A, Weverling GJ, et al. Legionnaires' disease at a Dutch flower show: prognostic factors and impact of therapy. Emerg Infect Dis. 2002;8(12):1448-54.
44. Yzerman EP, Den Boer JW, Lettinga KD, Schellekens J, Dankert J, Peeters M. Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires' disease in The Netherlands. J Clin Microbiol. 2002;40(9):3232-6.
45. Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol. 2001;39(10):3495-8.
46. Gutierrez F, Masia M, Rodriguez JC, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis. 2003;36(3):286-92.
47. Sorde R, Falco V, Lowak M, et al. Current and Potential Usefulness of Pneumococcal Urinary Antigen Detection in Hospitalized Patients With Community-Acquired Pneumonia to Guide Antimicrobial Therapy. 2011;171(2):166-72.
48. Roson B, Fernandez-Sabe N, Carratala J, et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis. 2004;38(2):222-6.
49. Stralin K, Kaltoft MS, Konradsen HB, Olcen P, Holmberg H. Comparison of two urinary antigen tests for establishment of pneumococcal etiology of adult community-acquired pneumonia. J Clin Microbiol. 2004;42(8):3620-5.
50. Andreo F, Ruiz-Manzano J, Prat C, et al. Utility of pneumococcal urinary antigen detection in diagnosing exacerbations in COPD patients. Respir Med. 2010;104(3):397-403.
51. Wegdam-Blans MC, Nabuurs-Franssen MN, Horrevorts AM, Peeters MF, Schneeberger PM, Bijlmer HA. [Laboratory diagnosis of acute Q fever]. Ned Tijdschr Geneeskd. 2010;154(37):A2388.
52. Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362(18):1708-19.
53. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(8):1003-32.
54. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1-62.
55. Don M, Valent F, Korppi M, et al. Efficacy of serum procalcitonin in evaluating severity of community-acquired pneumonia in childhood. Scand J Infect Dis. 2007;39(2):129-37.
56. Thayyil S, Shenoy M, Hamaluba M, Gupta A, Frater J, Verber IG. Is procalcitonin useful in early diagnosis of serious bacterial infections in children? Acta Paediatr. 2005;94(2):155-8.
57. Korppi M, Remes S, Heiskanen-Kosma T. Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings. Pediatr Pulmonol. 2003;35(1):56-61.
58. Daubin C, Parienti JJ, Fradin S, et al. Procalcitonin levels and bacterial aetiology among COPD patients admitted to the ICU with severe pneumonia: a prospective cohort study. BMC Infect Dis. 2009;9:157.
59. Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care. 2010;14(1):203.
60. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med. 2004;350(5):451-8.
61. Latour-Perez J, Alcala-Lopez A, Garcia-Garcia MA, et al. Diagnostic accuracy of sTREM-1 to identify infection in critically ill patients with systemic inflammatory response syndrome. Clin Biochem. 2010;43(9):720-4.
62. Bopp C, Hofer S, Bouchon A, Zimmermann JB, Martin E, Weigand MA. Soluble TREM-1 is not suitable for distinguishing between systemic inflammatory response syndrome and sepsis survivors and nonsurvivors in the early stage of acute inflammation. Eur J Anaesthesiol. 2009;26(6):504-7.
63. Blazquez Garrido RM, Espinosa Parra FJ, Alemany FL, et al. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis. 2005;40(6):800-6.
64. Grau S, Antonio JM, Ribes E, Salvado M, Garces JM, Garau J. Impact of rifampicin addition to clarithromycin in Legionella pneumophila pneumonia. Int J Antimicrob Agents. 2006;28(3):249-52.
65. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278(23):2080-4.
66. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Arch Intern Med. 2002;162(6):682-8.
67. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164(6):637-44.
68. Benenson R, Magalski A, Cavanaugh S, Williams E. Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. Acad Emerg Med. 1999;6(12):1243-8.
69. Marrie TJ, Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest. 2005;127(4):1260-70.
70. Bruns AH, Oosterheert JJ, Hustinx WN, Gaillard CA, Hak E, Hoepelman AI. Time for first antibiotic dose is not predictive for the early clinical failure of moderate-severe community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 2009;28(8):913-9.
71. Bax HI. Dutch Working Party on Antibiotic Policy (SWAB) guidelines for Antibacterial therapy of adult patients with Sepsis. 2010.
72. File TM, Jr., Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother. 2007;60(1):112-20.
73. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother. 2004;54(2):515-23.
74. el Moussaoui R., de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006;332(7554):1355.
75. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174(1):84-93.
76. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059-66.
77. Rhew DC, Tu GS, Ofman J, Henning JM, Richards MS, Weingarten SR. Early switch and early discharge strategies in patients with communityacquired pneumonia: a meta-analysis. Arch Intern Med. 2001;161(5):722-7.
78. Oosterheert JJ, Bonten MJ, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006;333(7580):1193.
79. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. 1999;159(20):2449-54.
80. Nathan RV, Rhew DC, Murray C, Bratzler DW, Houck PM, Weingarten SR. In-hospital observation after antibiotic switch in pneumonia: a national evaluation. Am J Med. 2006;119(6):512-7.
81. Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9782):2023-30.
82. Wunderink RG, Laterre PF, Francois B, et al. Recombinant Tissue Factor Pathway Inhibitor in Severe Community-Acquired Pneumonia: A Randomized Trial. Am J Respir Crit Care Med. 2011;183(11):1561-8.
83. Root RK, Lodato RF, Patrick W, et al. Multicenter, double-blind, placebocontrolled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med. 2003;31(2):367-73.
84. Maskell NA, Batt S, Hedley EL, Davies CW, Gillespie SH, Davies RJ. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am J Respir Crit Care Med. 2006;174(7):817-23.
85. Varkey B, Rose HD, Kutty CP, Politis J. Empyema thoracis during a ten-year period. Analysis of 72 cases and comparison to a previous study (1952 to 1967). Arch Intern Med. 1981;141(13):1771-6.
86. Heffner JE, Brown LK, Barbieri C, DeLeo JM. Pleural fluid chemical analysis in parapneumonic effusions. A meta- analysis. Am J Respir Crit Care Med. 1995;151(6):1700-8.
87. Laing FC, Filly RA. Problems in the application of ultrasonography for the evaluation of pleural opacities. Radiology. 1978;126(1):211-4.
88. Eibenberger KL, Dock WI, Ammann ME, Dorffner R, Hormann MF, Grabenwoger F. Quantification of pleural effusions: sonography versus radiography. Radiology. 1994;191(3):681-4.
89. Taryle DA, Good JT, Jr., Morgan EJ, III, Reller LB, Sahn SA. Antibiotic concentrations in human parapneumonic effusions. J Antimicrob Chemother. 1981;7(2):171-7.
90. Joseph J, Vaughan LM, Basran GS. Penetration of intravenous and oral ciprofloxacin into sterile and empyemic human pleural fluid. Ann Pharmacother. 1994;28(3):313-5.
91. Diacon AH, Theron J, Schuurmans MM, Van de Wal BW, Bolliger CT. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. Am J Respir Crit Care Med. 2004;170(1):49-53.
92. Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365(6):518-26.
93. Bouros D, Schiza S, Tzanakis N, Chalkiadakis G, Drositis J, Siafakas N. Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. A randomized, double-blind study. Am J Respir Crit Care Med. 1999;159(1):37-42.
94. Davies RJ, Traill ZC, Gleeson FV. Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax. 1997;52(5):416-21.
95. Cameron R, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev. 2008;(2):CD002312.
96. Diacon AH, Theron J, Schuurmans MM, Van de Wal BW, Bolliger CT. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. Am J Respir Crit Care Med. 2004;170(1):49-53.
97. Maskell NA, Davies CW, Nunn AJ, et al. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med. 2005;352(9):865-74.
98. Seymann GB. Community-acquired pneumonia: defining quality care. J Hosp Med. 2006;1(6):344-53.
99. Graffelman AW, Knuistingh NA, le Cessie S, Kroes AC, Springer MP, van den Broek PJ. Pathogens involved in lower respiratory tract infections in general practice. Br J Gen Pract. 2004;54(498):15-9.
100. Boersma WG, Lowenberg A, Holloway Y, Kuttschrutter H, Snijder JA, Koeter GH. Pneumococcal capsular antigen detection and pneumococcal serology in patients with community acquired pneumonia. Thorax. 1991;46(12):902-6.